Status: Not yet recruiting
An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia
The study design is a de-escalation of current atypical AP treatment to X/T at a maintenance dose of X/T established either at 100 mg xanomeline/20 mg trospium chloride BID (total daily dose 200 mg xanomeline/40 mg trospium chloride) or 125 mg xanomeline/30 mg trospium chloride BID (total daily dose 250 mg xanomeline/60 mg trospium chloride) based on participants' clinical response and/or tolerability. While the package insert for X/T provides guidance for clinicians on dosing, this study is designed to assess how transitioning will occur in the "real world" situation.
Participants needed: 100
Trial details
Phase: Phase 4Age: 18-65Biological sex: AllType: InterventionalSponsor: Collaborative Neuroscience Research, LLCUpdated: Apr 11, 2025Locations: 7
Eligibility criteria
Participant is aged 18 to 65 years, inclusive, at Screening. [+24]
Any primary DSM-5 disorder other than schizophrenia within 6 months before Scree... [+35]